A biopharmaceutical business focused on discovering.
AVEO’s successful use of its genetically designed mouse models to find these human-relevant biomarkers demonstrates the potential of AVEO’s preclinical tumor models in individual response prediction. ‘We believe these assessments reflect different aspects of the same underlying tumor biology and have potential for development as companion diagnostics in a wide selection of tumor types. Ongoing research involving these tests will help AVEO make educated decisions as we explore the use of these biomarkers inside our clinical programs,’ commented Tuan Ha-Ngoc, president and chief executive officer of AVEO Pharmaceuticals. (more…)